
    
      Randomized, single-center, single-blinded, controlled clinical trial. Adult patients (age
      between 18 and 65 years), regardless of sex, with second degree burns treated in outpatient
      regimen will be randomized (1:1) into two groups: 1% silver sulfadiazine and nanocrystalline
      silver.

      Primary outcome:

      - Proportion of lesions completely epithelialized within 15 days.

      Secondary outcomes:

        -  Time in days for complete epithelialization of the burned areas;

        -  Number of dressing changes;

        -  Level of pain associated with the application and removal of the dressings;

        -  Direct medical and non-medical costs;

        -  Need for surgery;

        -  Incidence of infection;

        -  Presence of local adverse reactions.
    
  